13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

23 trials found

diseases per page:

Showing 1 to 10 of 23 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05199688 (ClinicalTrials.gov)	February 28, 2023	3/12/2021	A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satral ...	A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Saf ...	Neuromyelitis Optica Spectrum Disorder;NMOSD	Drug: Satralizumab	Hoffmann-La Roche	NULL	Recruiting	2 Years	11 Years	All	8	Phase 3	France;Poland;United Kingdom;Argentina;Italy;Mexico;Ukraine;United States
2	NCT05269667 (ClinicalTrials.gov)	August 2, 2022	15/2/2022	A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention	SAkuraBonsai: Clinical, Imaging And Biomarker Open-Label Study In Neuromyelitis Optica Spectrum Diso ...	Neuromyelitis Optica Spectrum Disorder;NMOSD	Drug: Satralizumab 120 mg	Hoffmann-La Roche	Chugai Pharmaceutical Co.	Recruiting	18 Years	74 Years	All	100	Phase 4	United States;France;Italy;Japan;Korea, Republic of;Turkey;Canada;Germany;India
3	JPRN-jRCT2021220014	01/07/2022	25/06/2022	A Clinical, Imaging and Biomarker Study in Neuromyelitis Optica Spectrum Disorder (NMOSD) with Satra ...	SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISO ...	Neuromyelitis Optica Spectrum Disorder (NMOSD)	Satralizumab: 120 mg SC injection every 4 weeks (Q4W)	Regine Buffels	NULL	Pending	>= 18age old	<= 74age old	Both	100	Phase 4	United States;Canada;Italy;France;Germany;India;Korea;Turkey;Japan
4	EUCTR2019-004092-39-FR (EUCTR)	23/03/2022	22/12/2021	A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satral ...	A PHASE III, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE PHARMACOKINETICS, EFFICACY, SAF ...	Neuromyelitis Optica Spectrum Disorder (NMOSD) MedDRA version: 20.0;Level: LLT;Classification code 1 ...	Trade Name: Enspryng INN or Proposed INN: Satralizumab Product Name: Satralizumab Product Code: Ro 533- ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	8	Phase 3	United States;France;Mexico;Argentina;Poland;Ukraine;United Kingdom;Italy
5	EUCTR2021-001088-26-IT (EUCTR)	21/12/2021	18/10/2021	A Clinical, Imaging and Biomarker Study in Neuromyelitis Optica Spectrum Disorder (NMOSD) with Satra ...	SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISO ...	Neuromyelitis Optica Spectrum Disorder (NMOSD) MedDRA version: 21.1;Level: PT;Classification code 10 ...	Trade Name: Enspryng Product Name: satralizumab Product Code: [RO5333787] INN or Proposed INN: Satraliz ...	F. HOFFMANN - LA ROCHE LTD.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	France;United States;Canada;Turkey;Germany;Italy;Korea, Republic of;India
6	EUCTR2020-003413-35-BG (EUCTR)	16/04/2021	17/02/2021	A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALI ...	A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALI ...	Neuromyelitis Optic Spectrum Disorder MedDRA version: 21.1;Level: PT;Classification code 10077875;Te ...	Trade Name: Enspryng Product Name: Satralizumab Product Code: RO5333787 INN or Proposed INN: SATRALIZUM ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	127	Phase 3	United States;Taiwan;Spain;Ukraine;Turkey;United Kingdom;Italy;Hungary;Canada;Poland;Malaysia;Romani ...
7	JPRN-jRCT2031200333	02/03/2021	29/01/2021	A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALI ...	A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALI ...	Neuromyelitis Optica Spectrum Disorder (NMOSD)	Satralizumab: 120 mg SC injection every 4 weeks (Q4W)	Hans-Christian von Buedingen	NULL	Not Recruiting	Not applicable	Not applicable	Both	127	Phase 4	Italy;Taiwan;United States;Poland;Canada;United Kingdom;Ukraine;Bulgaria;Turkey;Korea;Romania;Georgi ...
8	NCT04660539 (ClinicalTrials.gov)	March 2, 2021	24/11/2020	A Study to Evaluate the Safety and Efficacy of Satralizumabin Participants With Neuromyelitis Optica ...	A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satrali ...	Neuromyelitis Optica Spectrum Disorder	Drug: satralizumab;Drug: azathioprine (AZA);Drug: mycophenolate mofetil (MMF);Drug: oral corticosteroid ...	Hoffmann-La Roche	NULL	Active, not recruiting	18 Years	N/A	All	119	Phase 3	United States;Bulgaria;Canada;Croatia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland ...
9	EUCTR2020-003413-35-IT (EUCTR)	10/02/2021	24/05/2021	A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALI ...	A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALI ...	Neuromyelitis Optic Spectrum Disorder MedDRA version: 21.1;Level: PT;Classification code 10077875;Te ...	Trade Name: Enspryng Product Name: Satralizumab Product Code: [RO5333787] INN or Proposed INN: SATRALIZ ...	F. HOFFMANN - LA ROCHE LTD.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	127	Phase 3	United States;Taiwan;Spain;Ukraine;Turkey;United Kingdom;Italy;Hungary;Canada;Poland;Malaysia;Romani ...
10	EUCTR2020-003413-35-HU (EUCTR)	05/02/2021	16/11/2020	A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALI ...	A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALI ...	Neuromyelitis Optic Spectrum Disorder MedDRA version: 21.1;Level: PT;Classification code 10077875;Te ...	Trade Name: Enspryng Product Name: Satralizumab Product Code: RO5333787 INN or Proposed INN: SATRALIZUM ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	127	Phase 3	United States;Taiwan;Spain;Ukraine;Turkey;United Kingdom;Italy;Hungary;Canada;Malaysia;Poland;Croati ...

First Previous1 2 3Next Last